膀性モノアミン輸送阻害剤:現在の用途と将来の方向性
Liana S Rosenthal1, Mena Farag2, N Ahmad Aziz3
1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lancet (London, England)
|August 9, 2025
まとめ
膀性モノアミントランスポーター2 (VMAT2) 阻害剤は,神経伝達物質の放出を調節することによって,運動および神経精神疾患の治療に不可欠です. VMAT2阻害剤の有効性と安全性を高める.
科学分野:
- 神経科学
- 薬理学について
- 遺伝学
背景:
- 膀性モノアミントランスポーター2 (VMAT2) は,神経伝達物質をシナプス膀に包装する上で重要な役割を果たします.
- VMAT2の調節不全は,様々な運動および神経精神疾患に関与しています.
研究 の 目的:
- 神経学的および精神学的状態の治療のためのVMAT2阻害剤の進歩をレビューする.
- 神経伝達におけるVMAT2の役割とその治療的影響を探求する.
主な方法:
- VMAT2阻害剤とそのメカニズムに関する最近の文献のレビュー.
- ハイパーキネティック運動障害における臨床有効性の分析
- VMAT2阻害剤の代謝に対する薬理学的影響の検討
主要な成果:
- テトラベナジン,デュテラベナジン,バルベナジンのようなVMAT2阻害剤は,ハンティントン病,遅発性運動障害,トゥレット症候群の管理に有効です.
- 阻害剤は神経伝達物質の貯蔵と放出を調節し,過度のシナプス活動を減少させます.
- 遺伝的変異はVMAT2阻害剤の代謝に影響し,個別化された投与が必要です.
結論:
- VMAT2阻害剤は,運動および神経精神疾患に対する重要な治療効果を提供します.
- 薬剤遺伝学では 精密医療によって 治療結果を最適化できます
- VMAT2阻害に関するさらなる研究は,神経学的および精神学的状態の治療用途を拡大する可能性があります.
さらに関連する動画
関連する概念動画
01:23Antidepressant Drugs: MAOIs and Other Agents
349
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
349
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.2K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.2K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
880
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
880
01:26Cholinergic Antagonists: Therapeutic Uses
873
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
873
01:25Adrenergic Agonists: Indirect-Acting Agents
1.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.8K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
615
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
615